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Bcr-Abl, a constitutively active cytoplasmic tyrosine 
kinase essential for the initiation of chronic myeloge-
nous leukemia (CML) is coded by the gene derived from 
the fusion of the breakpoint cluster region (BCR) gene 
on chromosome 22 and the Abelson leukemia onco-
gene (ABL) on chromosome 9. At diagnosis, up to 95% 
of CML cases have the characteristic t(9; 22)(q34; q112) 
reciprocal translocation giving the origin to Philadelphia 
chromosome [1]. Depending on the breakpoint region 
of the BCR gene implicated in the translocation, various 
Bcr-Abl chimeras have been observed: p190 Bcr-Abl, 
p210 Bcr-Abl and p230 Bcr-Abl [2]. The most frequent 
one is p210 Bcr-Abl, which is responsible for CML, while 
p190 Bcr-Abl is responsible for acute lymphoblastic 
leukemia (ALL). Rarely, the breakpoint in BCR gene 
occurs in μ-BCR region spanning exons 17–20 and 
a larger fusion protein p230 is encoded. Patients with 
this fusion demonstrate prominent neutrophil matura-
tion and/or conspicuous thrombocytosis.
The only structural difference between p190 and 
p210 Bcr-Abl is the presence of Dbl homology (DH) and 
pleckstrin homology (PH) domains in p210 Bcr-Abl. Thus, 
a complete understanding of the biological mechanisms 
underlying the origin of ALL and CML requires the charac-
terization of the signaling activities that reside within Bcr. 
The isolated recombinant DH domain of Bcr is suggested 
to be an activator of Rho GTPases [3]. The function of PH 
domain has not yet been clarified in details. Recently, PH 
domain has been shown to bind various phospholipids 
and to take part in protein-protein interactions [4]. The 
resulting Bcr-Abl fusion protein acts as an oncoprotein 
and the constitutive activation of tyrosine kinase activi-
ty contributes to Bcr-Abl mediated leukemogenesis. 
p210 Bcr-Abl unlike normal p145 c-Abl has been shown 
to localize predominantly in cytoplasm [5]. The ectopic ex-
pression of p210 Bcr-Abl seems to be a factor contributing 
to leukemic transformation of hematopoietic cells. In the 
cytoplasm Bcr-Abl interacts with multiple signal transduc-
tion pathways that transmit anti-apoptotic and mitogenic 
signals. The key pathways involve Ras, MAP kinases, the 
STAT family, PI3 kinase, and myc, among others [2, 6].
The aim of the study is to obtain the specific anti-
bodies recognizing Bcr domain and fusion region of 
Bcr-Abl and to study immunocytochemically the pat-
terns of intracellular distribution of Bcr and Bcr-Abl 
proteins in the cells of chronic myelogenous leukemia.
In this study, the gene constructs containing se-
quences coding for DН and РН domains of Bcr-Abl 
have been obtained, the corresponding fusion proteins 
were produced in bacteria, purified and used for the 
immunization. The polyclonal antibodies to Bcr domain 
and to region of Bcr-Abl fusion were obtained and the 
subcellular localization of Bcr-Abl and Bcr in K562 cells 
was examined. Our data should help us to understand 
the molecular mechanisms underlying the phenotypes 
of Bcr-Abl positive leukemias and to find new targets 
for therapeutic intervention.
MATERIALS AND METHODS
Cell line. Bcr-Abl positive K562 cells of blast phase 
of human chronic myelogenous leukemia were obtained 
from cell line depository of R.E. Kavetsky Institute of Ex-
perimental Pathology, Oncology and Radiobiology NAS 
of Ukraine. The cells were cultured in suspension in 5% 
CO2 — 95% air mixture at the temperature of 37 °C in RPMI 
1640 medium supplemented with 10% fetal bovine serum 
(Hyclone Laboratories, Logan, UT),  0.1% gentamycin 
(Hyclone), and 1% L-glutamine (Hyclone).
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Cloning of coding sequences of DН and РН do-
mains of BCR-ABL. Expression construct рDDВА3 based 
on рЕТ32b vector coding for DH domain of Bcr was de-
signed in the following way: The amplification product 
of cDNA corresponding to the region 1955–2810 b.p. 
according to GenBank X02596.1 was cloned in pET32b 
at EcoRI site. The recombinant protein was expressed in 
ВL21/DЕЗ strain of E. coli. Another expression construct 
pPDBA 138 designed on the basis of рЕТ32b vector 
was used to obtain the recombinant protein comprising 
PH domain of Bcr and Abl fragment corresponding to 
2744–3333 b.p. region of Bcr-Abl according to GenBank 
X02596.1. The details of cloning procedures are presented 
in [3]. The alignment of the coding sequences in both 
constructs is schematically given in Fig. 1.
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Fig. 1. Schematical alignment of the cloned fragments of Bcr-Abl 
in expression constructs рDDBA3 and рРDBA138
Purification of recombinant proteins and pro-
duction of polyclonal antibodies. The recombinant 
proteins DDВА3 and РDВА 138 were purified by affini-
ty chromatography on Ni-NTA agarose and dialyzed 
against PBS pH 7.4. The purity of antibodies was 
assessed by electrophoresis in agarose gel (Fig. 2). 
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Fig. 2. Electrophoregrams of purification stages of recombinant 
protein РDBA138: a, 1 — LMW standards; 2 — purified inclusion 
bodies; 3 — soluble fraction of recombinant protein РDBA138 af-
ter dialysis against PBS; b, isolation of recombinant proteins by 
affinity chromatography under the native conditions on Ni-NTA 
agarose: 1–7 stages of elution with step-wise imidasol gradient 
40, 60, 80, 100, 150, 200, 250 mМ
The purified proteins were used for producing poly-
clonal antibodies. The recombinant proteins mixed with 
complete Freund adjuvant were injected to the male 
rabbits, and in 8 and 12 weeks booster immunizations 
followed. The titer of specific antibodies was assessed 
in serum by immunoenzyme technique. The antibodies 
were depleted on BrCN-activated Sepharose (Аmersham 
Рhаrmасіа Віоtесh Іnс., USA) with immobilized total 
bacterial proteins of Е. соlі ВL21(DЕЗ) as well as the 
peptide expressed by pET32 itself. The specificity of 
the antibodies obtained was assessed by Western blot.
Immunochemical technique. K562 cells were 
used as a model for immunocytochemical study of 
Bcr and Bcr-Abl localization. The cells were fixed 
with formalin-acetone pH 7.6 and permeabilized with 
0.1% Triton X-100. The specimens were treated with 
anti-DDBA3 or anti-PDBA138 antibodies. EnVisionAP 
system (DAKO, Denmark) was used as the secondary 
antibody. The immunochemical staining was visuali-
zed upon cytochemical reaction with naphtol-AS-BI-
phosphate as the substrate of alkaline phosphatase.
RESULTS AND DISCUSSION
The results of Western blot with purified antibo dies 
against DDВАЗ and РDВА 138 proteins are given in 
Fig. 3. The lysates from K562 cells, the peripheral 
blood cells of CML patients and the healthy donors 
were used. Both anti-DDBA3 and anti-PDBA 138 reveal 
p210 and p160 proteins in K562 cells and in cells from 
CML patients. The cross-reactivity may be explained 
by the presence of the short overlapping Bcr se-
quence, 22 amino acid residues in length (see Fig. 1), 
in both recombinant proteins. Nevertheless, the affinity 
of binding seems to be more pronounced in the case 
of anti-PDBA 138 antibody. Therefore, we attempted 
to use both antibodies in the analysis of intracellular 
distribution Bcr and Bcr-Abl in K562 cells.
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Fig. 3. Western blot with polyclonal anti-DDBA3 and anti-PD-
BA138 antibodies against the corresponding recombinant proteins. 
а, b — detection of chimerical protein Bcr-Abl (210 kD) and its 
normal analogue (160 kD) in polymorphonuclear cells of healthy 
donors and CML patients with polyclonal anti-DDBA3 (a) and anti-
PDBA138 (b) antibodies: 1, 4 — healthy donors; 2, 3, 6 — CML 
patients; 5 — K562 cells; 7 — HMW protein standard (Sigma, USA)
The polyclonal antibodies against DDВАЗ and РDВА 
138 proteins recognizing different regions of Bcr-Abl hy-
brid protein allows one to analyze the intracellular location 
of Bcr-Abl as well as Bcr proteins in CML cells in vivo. The 
results of immunocytochemical analysis of K562 cells 
with antibodies against DDВАЗ and РDВА 138 proteins 
are presented in Fig. 4. Bcr protein is located predomi-
nantly perinuclearly, while anti-PDBA138 antibody against 
Experimental Oncology 32, 81–83, 2010 (June) 83
hybrid Bcr-Abl protein is revealed predominantly in cell 
periphery, namely on cell membranes. Therefore, the 
anti-DDBA3 and anti-PDBA138 antibodies with relative 
specificity to corresponding recombinant proteins differ by 
the patterns of intracellular reactivity with Bcr- and Bcr-Abl 
related structures.
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Fig. 4. Topography of Bcr and Bcr-Abl in K562 cells assessed with 
polyclonal anti-DDBA3 and anti-PDBA138 antibodies against the 
corresponding recombinant proteins: a — K562 cells, MGG stain-
ing, x 900; b — perinuclear pattern of Bcr distribution (anti-DDBA3); 
c — membrane pattern of Bcr-Abl distribution (anti-PDBA138)
In K562 cells transformed with pEGFP-Bcr-Abl con-
struct, the protein has predominantly cytoplasmic localiza-
tion generating cortical-F-actin ring [7] due to actin-bind-
ing domain in Abl moiety of Bcr-Abl hybrid protein [3, 8]. 
Also, in 32D myeloid cells Bcr-Abl locates on vesicle-like 
structures that lacked detectable F-actin [9]. Such bind-
ing is not affected by mutations in actin-binding domain. 
Our previous data [10] seem to hint at the mechanisms 
of such location. Namely, PH domain has been shown to 
bind to the membrane of Golgi complex, in particular with 
PIP(3) and PIP(4). The different patterns of the intracellular 
localization of Bcr and Bcr-Abl may be attributable to the 
different domains interacting with different multiprotein 
complexes. PDZ-binding domain in C-terminal part of Bcr 
provides for its interaction with AF-6 protein facilitating Ras 
binding producing the multimeric complex. As a result, Ras 
and ERK are down-regulated [11]. Besides, PDZ-binding 
domain provides for the interaction between Bcr and the 
apical PDZ-K-1and Mint 3, the latter being the component 
of the vesicular trafficking in the secretory pathway [12]. 
For understanding the role of Bcr in cell biology, the fact 
of its displacement to the membrane upon the effects of 
growth factors is of high importance [13].
Thus, our data show that in K562 CML cells Bcr-Abl 
is predominantly localized to the cell periphery. This 
fact seems to be explained by the presence of actin-
binding domain in Bcr-Abl hybrid protein. On the other 
hand, the localization of Bcr may be partly explained by 
the presence of PH and PDZ-binding domains.
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